Non-muscle invasive bladder cancer is common, recurrent, and often misunderstood. Urologist Jed Ferguson, M.D., and urologic oncologist Chaz Payton, M.D., explain how it differs from muscle invasive disease, why recurrence increases the risk of progression, and the complex factors that determine treatment sequencing. Learn about UAB’s clinical trials and emerging therapies that aim to preserve the bladder without compromising care.